PPIs and clopidogrel: the band plays on

Area of Science:

• Cardiology
• Pharmacology
• Gastroenterology

Background:

• Controversy exists regarding proton pump inhibitor (PPI) and clopidogrel co-therapy safety.
• Some studies suggest PPIs increase adverse cardiovascular events in clopidogrel users; others do not.
• Regulatory agencies have issued warnings about certain PPIs with clopidogrel.

Discussion:

• A European outcomes study found increased cardiovascular and gastrointestinal adverse events in clopidogrel users taking PPIs.
• The observed association is potentially explained by channeling bias.
• Channeling bias may occur if patients at higher risk for gastrointestinal events are preferentially prescribed PPIs.

Key Insights:

• The study provides European data on PPI-clopidogrel co-therapy outcomes.
• Findings suggest a need to re-evaluate the safety concerns surrounding this drug combination.
• Channeling bias is a critical factor to consider in interpreting observational data.

Outlook:

• Further research is needed to elucidate the true relationship between PPIs and clopidogrel.
• Clinical guidelines may require revision based on future evidence.
• Understanding confounding factors like channeling bias is crucial for patient safety.